(:VRX)
Business Focus: N/A
Aug 30, 2022 11:28 pm ET
Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes
LAVAL, Quebec, Aug. 30, 2022 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ( "Company") announced today that it has commenced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (subject to increase or decrease by the Offerors, the "Maximum New Secured Notes Amount") of new secured notes, comprised of (i) up to $2.5 billion in aggregate principal amount (the "Maximum First Lien Notes Amount") of new 11.00% First Lien Secured Notes due 2028 (the "New Firs
Aug 30, 2022 11:28 pm ET
Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes
LAVAL, Quebec, Aug. 30, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ( "Company") announced today that it has commenced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (subject to increase or decrease by the Offerors, the "Maximum New Secured Notes Amount") of new secured notes, comprised of (i) up to $2.5 billion in aggregate principal amount (the "Maximum First Lien Notes Amount") of new 11.00% First Lien Secured Notes due 2028 (the "N
Apr 13, 2021 06:58 am ET
Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
All Primary and Secondary Endpoints Were Achieved
Feb 24, 2021 05:59 am ET
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance
LAVAL, Quebec, Feb. 24, 2021 /PRNewswire/ --
Feb 24, 2021 05:59 am ET
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance
LAVAL, Quebec, Feb. 24, 2021 /CNW/ --
Jan 20, 2021 06:00 am ET
Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium
Bausch + Lomb Will Also Host Presentation on Technologies that Can Help Create Efficiencies in Fitting Zenlens™ Scleral Lenses on Patients
Jan 20, 2021 06:00 am ET
Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium
Bausch + Lomb Will Also Host Presentation on Technologies that Can Help Create Efficiencies in Fitting Zenlens™ Scleral Lenses on Patients
Oct 27, 2020 06:58 am ET
Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses
First Preloaded Toric Available in the United States and Monofocal Option Combine Consistent IOL Delivery with Outstanding Visual Outcomes of enVista®
Oct 27, 2020 06:58 am ET
Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses
First Preloaded Toric Available in the United States and Monofocal Option Combine Consistent IOL Delivery with Outstanding Visual Outcomes of enVista®
Oct 22, 2020 07:00 am ET
Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting
Eleven Scientific Posters to be Featured
Oct 22, 2020 07:00 am ET
Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting
Eleven Scientific Posters to be Featured
Oct 12, 2020 07:00 am ET
Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12
LAVAL, QC and NEW YORK, Oct. 12, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, its leading global eye health business, and Eyenovia, Inc., (NASDAQ: EYEN) ("Eyenovia"), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that an affiliate of Bausch Health has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigat
Sep 23, 2020 07:00 am ET
Bausch Health Releases Annual Corporate Social Responsibility Report
Includes Special Report on Global COVID-19 Response and Commitment to Diversity & Inclusion
Sep 09, 2020 07:00 am ET
Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare Conference
LAVAL, QC, Sept. 9, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and CEO; Sam Eldessouky, senior vice president and corporate controller; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020 at 1:15 p.m. ET.
Jul 31, 2020 04:43 pm ET
Bausch Health Resolves Legacy SEC Investigation
LAVAL, QC, July 31, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), f/k/a Valeant Pharmaceuticals International, Inc. ("Valeant"), today announced the successful resolution of the legacy investigation by the U.S. Securities and Exchange Commission ("SEC") regarding Valeant's former relationship with Philidor Rx Services, LLC and certain of Valeant's accounting practices, policies and public disclosures relating to the 2014 and 2015 reporting periods. The settlement will fully resolve the investigation, which commenced in the fourth quarter of 20
Jul 31, 2020 04:43 pm ET
Bausch Health Resolves Legacy SEC Investigation
LAVAL, QC, July 31, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), f/k/a Valeant Pharmaceuticals International, Inc. ("Valeant"), today announced the successful resolution of the legacy investigation by the U.S. Securities and Exchange Commission ("SEC") regarding Valeant's former relationship with Philidor Rx Services, LLC and certain of Valeant's accounting practices, policies and public disclosures relating to the 2014 and 2015 reporting periods. The settlement will fully resolve the investigation, which commenced in the fourth quarte
May 21, 2020 07:00 am ET
Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference
LAVAL, Quebec, May 21, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual Goldman Sachs Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. EDT.
May 21, 2020 07:00 am ET
Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference
LAVAL, Quebec, May 21, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual Goldman Sachs Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. EDT.
Apr 29, 2020 04:50 pm ET
Bausch Health Announces 2020 Annual Meeting Of Shareholder Results
LAVAL, Quebec, April 29, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the election of the eleven directors nominated at its 2020 annual meeting of shareholders held on April 28, 2020. The detailed results of the vote for the election of directors are set out below:
Apr 29, 2020 04:50 pm ET
Bausch Health Announces 2020 Annual Meeting Of Shareholder Results
LAVAL, Quebec, April 29, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the election of the eleven directors nominated at its 2020 annual meeting of shareholders held on April 28, 2020. The detailed results of the vote for the election of directors are set out below:
Feb 19, 2020 03:40 pm ET
Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of Existing Senior Secured Notes
LAVAL, Quebec, Feb. 19, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it is seeking to amend and refinance its existing credit agreement (the "Credit Agreement") in order to extend and reprice its existing term loan facility and revolving credit facility and make certain other amendments to the terms of the facilities in connection therewith (collectively, the "Credit Agreement Refinancing"). Additionally, the Company intends, subject to market conditions, to have Bausch Health Americas, Inc. ("BHA"), a wholly-owned indirec
Feb 03, 2020 06:00 am ET
Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program
Students Treated for Dermatologic Conditions Can Apply for the Scholarship Through April 27, 2020
Oct 10, 2019 07:58 am ET
Ortho Dermatologics Announces 2019 Aspire Higher Scholarship Recipients
$10,000 Scholarships Awarded to Nine Students Affected by Dermatologic Conditions
Oct 10, 2019 07:58 am ET
Ortho Dermatologics Announces 2019 Aspire Higher Scholarship Recipients
$10,000 Scholarships Awarded to Nine Students Affected by Dermatologic Conditions
Jul 08, 2019 08:00 am ET
Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6
LAVAL, Quebec, July 8, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2019 financial results on Tuesday, Aug. 6, 2019. Bausch Health will host a conference call and live web cast at 8:00 a.m. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.
Jul 08, 2019 08:00 am ET
Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6
LAVAL, Quebec, July 8, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2019 financial results on Tuesday, Aug. 6, 2019. Bausch Health will host a conference call and live web cast at 8:00 a.m. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.
Dec 05, 2018 07:00 am ET
Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses
BRIDGEWATER, N.J., Dec. 5, 2018 /CNW/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first multifocal toric lens to be available as a standard offering in the eye care professional's fit set. The most advanced soft contact lens design in the history of Bausch + Lomb, this monthly silicone hydrogel lens builds upon the success of Bausch +
Dec 05, 2018 07:00 am ET
Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses
BRIDGEWATER, N.J., Dec. 5, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first multifocal toric lens to be available as a standard offering in the eye care professional's fit set. The most advanced soft contact lens design in the history of Bausch + Lomb, this monthly silicone hydrogel lens builds upon the success of B
Oct 30, 2018 08:00 am ET
Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States
LAVAL, Quebec, Oct. 30, 2018 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. launch of ALTRENOTM (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. ALTRENO Lotion is the first and only tretinoin available in a lotion for acne. ALTRENO Lotion has been shown to be effective and generally well-tolerated, and is provided in a formulation with known moisturizers hyaluronic acid, glycerin and co
Oct 30, 2018 08:00 am ET
Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States
LAVAL, Quebec, Oct. 30, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. launch of ALTRENOTM (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. ALTRENO Lotion is the first and only tretinoin available in a lotion for acne. ALTRENO Lotion has been shown to be effective and generally well-tolerated, and is provided in a formulation with known moisturizers hyaluronic acid, glycerin
Oct 11, 2018 08:00 am ET
Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology
ALTRENO Lotion Provides Statistically Significant Greater Efficacy Over Vehicle with a Favorable Safety and Tolerability Profile in Two Pivotal Clinical Trials1
Oct 11, 2018 08:00 am ET
Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology
ALTRENO Lotion Provides Statistically Significant Greater Efficacy Over Vehicle with a Favorable Safety and Tolerability Profile in Two Pivotal Clinical Trials1
Jul 09, 2018 08:00 am ET
Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%
PDUFA Date Set for February 25, 2019
Jul 09, 2018 08:00 am ET
Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%
PDUFA Date Set for February 25, 2019
Jun 26, 2018 08:00 am ET
Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine)
LOUISVILLE, Ky. and BRIDGEWATER, N.J., June 26, 2018 /PRNewswire/ -- US WorldMeds, LLC and Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant"), today announced that they have entered into an exclusive agreement to co-promote US WorldMeds' LUCEMYRA™ (lofexidine). The U.S. Food and Drug Administration ("FDA") approved
Jun 19, 2018 02:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX
NEW YORK, June 19, 2018 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Jun 19, 2018 02:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX
NEW YORK, June 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Jun 19, 2018 12:03 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Valeant Pharmaceuticals International, Inc. (VRX)
NEW YORK, June 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/vrx.
Jun 18, 2018 08:00 am ET
FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion
LAVAL, Quebec, June 18, 2018 /CNW/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for DUOBRII™1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis.
Jun 18, 2018 08:00 am ET
FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion
LAVAL, Quebec, June 18, 2018 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for DUOBRII™1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis.
Jun 14, 2018 08:00 am ET
Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops
Now Available at Major U.S. Retailers
Jun 14, 2018 08:00 am ET
Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops
Now Available at Major U.S. Retailers
Jun 12, 2018 08:00 am ET
Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins
LAVAL, Quebec, June 12, 2018 /CNW/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), today announced the introduction of Ocuvite® Blue Light eye vitamins, a nutritional supplement formulated with lutein and zeaxanthin, the two carotenoid pigments naturally found in the eye. This formulation of eye nutrients includes high levels of lutein and helps protect eyes from the blue light that reaches the macula, which is responsible for our central vision.
Jun 12, 2018 08:00 am ET
Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins
LAVAL, Quebec, June 12, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), today announced the introduction of Ocuvite® Blue Light eye vitamins, a nutritional supplement formulated with lutein and zeaxanthin, the two carotenoid pigments naturally found in the eye. This formulation of eye nutrients includes high levels of lutein and helps protect eyes from the blue light that reaches the macula, which is responsible for our central vision.
Jun 08, 2018 06:00 pm ET
Securities Class Action Filed on Behalf of Persons or Entities That Traded Certain Derivative Securities of Valeant Pharmaceuticals International, Inc. During the Period January 4, 2013 Through August
Entwistle & Cappucci LLP (“Entwistle & Cappucci”) today announced that
it has filed a securities class action lawsuit on behalf of persons or
entities that purchased call options and/or sold put options on Valeant
Pharmaceuticals International, Inc. (NYSE: VRX) (“Valeant” or the
“Company”) common stock during the period January 4, 2013 through August
11, 2016, inclusive (the “Class Period”), and who were damaged thereby
(the “Class”). The case was filed in the United States District Court
for the District of New Jersey, Case No. 3:18-cv-10246, a
Jun 05, 2018 08:25 am ET
Detailed Research: Economic Perspectives on Central European Media Enterprises, Valeant Pharmaceuticals International, Nice, NCS Multistage, NewLink Genetics, and Colliers International Group — What D
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Central European Media Enterprises Ltd. (NASDAQ:CETV), Valeant...
Jun 01, 2018 04:15 pm ET
Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes
LAVAL, Quebec, June 1, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it has entered into a Fourth Amended & Restated Credit and Guaranty Agreement (the "New Credit Agreement") effectuating a full refinancing of its secured revolving and term loan credit facilities, and closed the previously announced offering of 8.500% Senior Notes due 2027 by Valeant Pharmaceuticals International ("VPI"), a wholly owned indirect subsidiary of Valeant. Valeant also announced that on July 2, 2018, it will redeem the remaining $6
Jun 01, 2018 04:15 pm ET
Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes
LAVAL, Quebec, June 1, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it has entered into a Fourth Amended & Restated Credit and Guaranty Agreement (the "New Credit Agreement") effectuating a full refinancing of its secured revolving and term loan credit facilities, and closed the previously announced offering of 8.500% Senior Notes due 2027 by Valeant Pharmaceuticals International ("VPI"), a wholly owned indirect subsidiary of Valeant. Valeant also announced that on July 2, 2018, it will redeem the remai
May 31, 2018 08:30 am ET
Salix To Highlight New Clinical Data During Digestive Disease Week
Oral Presentation and Eight Posters to be Featured
May 31, 2018 08:30 am ET
Salix To Highlight New Clinical Data During Digestive Disease Week
Oral Presentation and Eight Posters to be Featured
May 17, 2018 05:00 pm ET
Valeant Announces Pricing Of Private Offering Of Notes
LAVAL, Quebec, May 17, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has priced its previously announced offering of $750,000,000 aggregate principal amount of 8.50% unsecured senior notes due 2027 (the "Notes"). The Notes were offered at par. The offering is expected to close on or about June 1, 2018. As previously announced, the Company is seeking to amend and restate its existing credit agreement (as amended and
May 17, 2018 05:00 pm ET
Valeant Announces Pricing Of Private Offering Of Notes
LAVAL, Quebec, May 17, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has priced its previously announced offering of $750,000,000 aggregate principal amount of 8.50% unsecured senior notes due 2027 (the "Notes"). The Notes were offered at par. The offering is expected to close on or about June 1, 2018. As previously announced, the Company is seeking to amend and restate its existing credit agreement (as amen
May 17, 2018 07:15 am ET
Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans
LAVAL, Quebec, May 17, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has launched an offering of $750,000,000 aggregate principal amount of unsecured senior notes due 2027 (the "Notes"). As previously announced, the Company is seeking to amend and restate its existing credit agreement (as amended and restated, the "New Credit Agreement") and borrow $4.565 billion of new Term B loans (the "New Term B Loans") under t
May 17, 2018 07:15 am ET
Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans
LAVAL, Quebec, May 17, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has launched an offering of $750,000,000 aggregate principal amount of unsecured senior notes due 2027 (the "Notes"). As previously announced, the Company is seeking to amend and restate its existing credit agreement (as amended and restated, the "New Credit Agreement") and borrow $4.565 billion of new Term B loans (the "New Term B Loans")
May 15, 2018 08:00 am ET
Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference
LAVAL, Quebec, May 15, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance and chief financial officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Barclays High Yield Bond and Syndicated Loan Conference in Colorado Springs, Colo. on May 22, 2018 at 10:10 a.m. MDT (12:10 p.m. EDT).
May 15, 2018 08:00 am ET
Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference
LAVAL, Quebec, May 15, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance and chief financial officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Barclays High Yield Bond and Syndicated Loan Conference in Colorado Springs, Colo. on May 22, 2018 at 10:10 a.m. MDT (12:10 p.m. EDT).
May 15, 2018 07:49 am ET
VRX Investor Alert: Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors
BOSTON, May 15, 2018 /PRNewswire/ -- Kyros Law Offices is alerting investors of Valeant Pharmaceuticals Intl (NYSE:VRX) that it is filling legal claims against the company for possible securities fraud violations committed by Valeant Pharmaceuticals Intl (NYSE:VRX).
May 10, 2018 08:30 am ET
Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference
LAVAL, Quebec, May 10, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 16, 2018 at 10:40 a.m. PDT (1:40 p.m. EDT).
May 10, 2018 08:30 am ET
Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference
LAVAL, Quebec, May 10, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 16, 2018 at 10:40 a.m. PDT (1:40 p.m. EDT).
May 10, 2018 07:00 am ET
Valeant To Seek Refinancing of its Existing Credit Agreement
LAVAL, Quebec, May 10, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it is seeking to amend and restate its existing credit agreement (the "Credit Agreement") and borrow $3.815 billion of new Term B loans (the "New Term B Loans") under the Credit Agreement. The amendment and restatement is expected to have the effect of (i) extending the maturity date of the revolving facility to five years from the closing date, in an amount up to $1.2 billion (subject to a springing maturity with respect to the earlier mat
May 10, 2018 07:00 am ET
Valeant To Seek Refinancing of its Existing Credit Agreement
LAVAL, Quebec, May 10, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it is seeking to amend and restate its existing credit agreement (the "Credit Agreement") and borrow $3.815 billion of new Term B loans (the "New Term B Loans") under the Credit Agreement. The amendment and restatement is expected to have the effect of (i) extending the maturity date of the revolving facility to five years from the closing date, in an amount up to $1.2 billion (subject to a springing maturity with respect to the earlier maturity o
May 09, 2018 09:31 am ET
Thinking about buying stock in Advanced Micro Devices, Blink Charging, Disney, Valeant Pharmaceuticals and Walmart Stores?
CHICAGO, May 9, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, BLNK, DIS, VRX, and WMT.
May 08, 2018 07:00 am ET
Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance
LAVAL, Quebec, May 8, 2018 /PRNewswire/ --
May 08, 2018 07:00 am ET
Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance
LAVAL, Quebec, May 8, 2018 /CNW/ --
May 08, 2018 07:00 am ET
Valeant Will Become Bausch Health Companies Inc.
Bausch Health Companies Inc. Accurately Represents the Breadth of the Company Today and Reflects the Innovative Legacy of the Bausch Name
May 08, 2018 07:00 am ET
Valeant Will Become Bausch Health Companies Inc.
Bausch Health Companies Inc. Accurately Represents the Breadth of the Company Today and Reflects the Innovative Legacy of the Bausch Name
May 07, 2018 07:30 pm ET
Safirstein Metcalf LLP and HGT Law Remind Investors That a Shareholder Opt-out Lawsuit was Filed on Behalf of Retail Investors and Invite Investors to Contact the Firms - VRX
Safirstein Metcalf LLP and HGT Law remind investors that a shareholder “opt-out” lawsuit (“Lawsuit”) has been filed on behalf of a group of retail investors (“Investors”) against Valeant Pharmaceuticals International, Inc. (“Valeant”) and its...
May 07, 2018 08:00 am ET
Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine
Now Available at Major U.S. Retailers
May 07, 2018 08:00 am ET
Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine
Now Available at Major U.S. Retailers
May 07, 2018 07:00 am ET
Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies
BRIDGEWATER, N.J., May 7, 2018 /PRNewswire/ -- Salix Pharmaceuticals, Ltd. ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), and its partner Norgine B.V. ("Norgine") announced today that the U.S. Food and Drug Administration (FDA) has approved PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), a lower-volume (1L
May 07, 2018 07:00 am ET
Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies
BRIDGEWATER, N.J., May 7, 2018 /CNW/ -- Salix Pharmaceuticals, Ltd. ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), and its partner Norgine B.V. ("Norgine") announced today that the U.S. Food and Drug Administration (FDA) has approved PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), a lower-volume (1L) polye
May 03, 2018 08:00 am ET
Valeant To Participate At Goldman Sachs Third Annual Leveraged Finance Conference
LAVAL, Quebec, May 3, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer, is scheduled to participate at the Goldman Sachs Third Annual Leveraged Finance Conference in Rancho Palos Verdes, Calif. on Thursday, May 10, 2018 at 2:10 p.m. PDT (5:10 p.m. EDT).
May 03, 2018 08:00 am ET
Valeant To Participate At Goldman Sachs Third Annual Leveraged Finance Conference
LAVAL, Quebec, May 3, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer, is scheduled to participate at the Goldman Sachs Third Annual Leveraged Finance Conference in Rancho Palos Verdes, Calif. on Thursday, May 10, 2018 at 2:10 p.m. PDT (5:10 p.m. EDT).
May 02, 2018 08:00 pm ET
Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection
LAVAL, Quebec, May 2, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that the U.S. District Court for the District of New Jersey has granted a motion for partial summary judgment of validity of a formulation patent for RELISTOR® (methylnaltrexone bromide) Injection. The ruling prevents generic competition in the United States until 2024.
May 02, 2018 08:00 pm ET
Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection
LAVAL, Quebec, May 2, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that the U.S. District Court for the District of New Jersey has granted a motion for partial summary judgment of validity of a formulation patent for RELISTOR® (methylnaltrexone bromide) Injection. The ruling prevents generic competition in the United States until 2024.
May 02, 2018 08:26 am ET
Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication
Lenses Can Be Worn for Up to Six Nights and Seven Days Continuously
May 02, 2018 08:26 am ET
Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication
Lenses Can Be Worn for Up to Six Nights and Seven Days Continuously
May 01, 2018 08:10 pm ET
Valeant Announces 2018 Annual Meeting Results
LAVAL, Quebec, May 1, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today the election of the ten directors nominated at its 2018 annual meeting of shareholders held on April 30, 2018. The detailed results of the vote for the election of directors are set out below:
Apr 27, 2018 08:00 am ET
Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting
LAVAL, Quebec, April 27, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company, and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), announced today that nearly a dozen scientific posters will highlight the results of studies featuring several of the company's current product offerings and pipeline programs in its Consumer Health Care, Pharmaceuticals and Surgical businesses during the Association for Research in Vision and Ophthalmology (ARVO) meeting in Honolulu from April 29 - May 3, 2018.
Apr 27, 2018 08:00 am ET
Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting
LAVAL, Quebec, April 27, 2018 /CNW/ -- Bausch + Lomb, a leading global eye health company, and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), announced today that nearly a dozen scientific posters will highlight the results of studies featuring several of the company's current product offerings and pipeline programs in its Consumer Health Care, Pharmaceuticals and Surgical businesses during the Association for Research in Vision and Ophthalmology (ARVO) meeting in Honolulu from April 29 - May 3, 2018.
Apr 19, 2018 08:00 am ET
Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program
Recycling Program Has Diverted More than 14,000 Pounds of Waste From Landfills
Apr 19, 2018 08:00 am ET
Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program
Recycling Program Has Diverted More than 14,000 Pounds of Waste From Landfills
Apr 12, 2018 04:15 pm ET
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
LAVAL, Quebec, April 12, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Valeant Pharmaceuticals International, a wholly owned indirect subsidiary of Valeant, will redeem $150 million aggregate principal amount of its outstanding 6.375% Senior Unsecured Notes due 2020 (the "Notes"), using cash on hand, on May 14, 2018 and issued today an irrevocable notice of redemption for the Notes. The Notes were originally issued in 2012. Once the Notes have been redeemed, Valeant's total long-term debt will be approximately $25.4 billion.
Apr 12, 2018 04:15 pm ET
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
LAVAL, Quebec, April 12, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Valeant Pharmaceuticals International, a wholly owned indirect subsidiary of Valeant, will redeem $150 million aggregate principal amount of its outstanding 6.375% Senior Unsecured Notes due 2020 (the "Notes"), using cash on hand, on May 14, 2018 and issued today an irrevocable notice of redemption for the Notes. The Notes were originally issued in 2012. Once the Notes have been redeemed, Valeant's total long-term debt will be approximately $25.4 billion.
Apr 12, 2018 02:51 pm ET
Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration
LAVAL, Quebec, April 12, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that the Arbitral Tribunal issued a decision (rendered on April 9, 2018) relating to the arbitration between Santarus Inc. and Valeant Pharmaceuticals Ireland (collectively "Valeant"), and Cosmo Technologies Ltd. and Cosmo Technologies III Ltd. (collectively, "Cosmo"), the licensor of certain intellectual property rights in, and supplier of, Valeant's UCERIS® extended release tablets. The arbitration focused on Cosmo's allegations that Valeant had breached the License Agr
Apr 12, 2018 02:51 pm ET
Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration
LAVAL, Quebec, April 12, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that the Arbitral Tribunal issued a decision (rendered on April 9, 2018) relating to the arbitration between Santarus Inc. and Valeant Pharmaceuticals Ireland (collectively "Valeant"), and Cosmo Technologies Ltd. and Cosmo Technologies III Ltd. (collectively, "Cosmo"), the licensor of certain intellectual property rights in, and supplier of, Valeant's UCERIS® extended release tablets. The arbitration focused on Cosmo's allegations that Valeant had breached the License Agreement
Apr 11, 2018 08:00 am ET
Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery
More than 20 Podium Presentations, Posters and Films to be Featured
Apr 11, 2018 08:00 am ET
Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery
More than 20 Podium Presentations, Posters and Films to be Featured
Apr 10, 2018 07:33 pm ET
Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes
LAVAL, Quebec, April 10, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") announced today the expiration of the cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly owned indirect subsidiary of Valeant, incorporated in Delaware, to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"). Valeant was the Offeror for
Apr 10, 2018 07:33 pm ET
Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes
LAVAL, Quebec, April 10, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") announced today the expiration of the cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly owned indirect subsidiary of Valeant, incorporated in Delaware, to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"). Valeant was the Offeror for the not
Apr 09, 2018 07:45 am ET
New Research Coverage Highlights SINOPEC Shangai Petrochemical, Aurinia Pharmaceuticals, Valeant Pharmaceuticals International, NTT DOCOMO, Southern Missouri, and KNOT Offshore Partners LP — Consolida
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SINOPEC Shangai Petrochemical Company, Ltd. (NYSE:SHI),...
Apr 09, 2018 07:00 am ET
Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology
DUOBRII Demonstrated Significant Superiority Over Vehicle As Early As Two Weeks
Apr 09, 2018 07:00 am ET
Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology
DUOBRII Demonstrated Significant Superiority Over Vehicle As Early As Two Weeks
Apr 06, 2018 08:30 am ET
EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis
Top line Data expected in Q3 2018
Apr 06, 2018 08:00 am ET
Valeant Will Release First-Quarter 2018 Financial Results On May 8
LAVAL, Quebec, April 6, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") will release its first-quarter 2018 financial results on Tuesday, May 8, 2018. Valeant will host a conference call and live web cast at 8:00 a.m. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Valeant web site prior to the start of the call.
Apr 06, 2018 08:00 am ET
Valeant Will Release First-Quarter 2018 Financial Results On May 8
LAVAL, Quebec, April 6, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") will release its first-quarter 2018 financial results on Tuesday, May 8, 2018. Valeant will host a conference call and live web cast at 8:00 a.m. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Valeant web site prior to the start of the call.
Apr 03, 2018 08:00 am ET
Salix Launches 'Let's Talk 2' IBS Awareness Campaign
Let's Talk 2 Encourages Patients and Their Health Care Providers to Have 2-Way Conversations About Irritable Bowel Syndrome with Diarrhea (IBS-D)
Apr 03, 2018 08:00 am ET
Salix Launches 'Let's Talk 2' IBS Awareness Campaign
Let's Talk 2 Encourages Patients and Their Health Care Providers to Have 2-Way Conversations About Irritable Bowel Syndrome with Diarrhea (IBS-D)
Mar 26, 2018 07:00 am ET
Valeant and One of its Subsidiaries Announce Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes
LAVAL, Quebec, March 26, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly owned indirect subsidiary of Valeant, incorporated in Delaware, to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the
Mar 26, 2018 07:00 am ET
Valeant and One of its Subsidiaries Announce Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes
LAVAL, Quebec, March 26, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly owned indirect subsidiary of Valeant, incorporated in Delaware, to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticip
Mar 14, 2018 08:15 am ET
Report: Developing Opportunities within NRG Yield, Stitch Fix, Encana, Valeant Pharmaceuticals International, Orbotech, and CoreCivic, Inc. — Future Expectations, Projections Moving into 2018
NEW YORK, March 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NRG Yield, Inc. (NYSE:NYLD), Stitch Fix,...
Mar 12, 2018 07:42 pm ET
Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount
LAVAL, Quebec, March 12, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly owned subsidiary of Valeant, incorporated in Delaware, announced today that they have increased the maximum aggregate principal amount of their respective outstanding notes listed in the table below (collectively, the "Notes") that they may purchase pursuant to the previously announced cash tender offers (collectively, the "Tender Offer," and each offer to purchase
Mar 12, 2018 07:42 pm ET
Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount
LAVAL, Quebec, March 12, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly owned subsidiary of Valeant, incorporated in Delaware, announced today that they have increased the maximum aggregate principal amount of their respective outstanding notes listed in the table below (collectively, the "Notes") that they may purchase pursuant to the previously announced cash tender offers (collectively, the "Tender Offer," and each offer to purchase a serie
Mar 12, 2018 07:40 pm ET
Valeant Announces Pricing of Private Offering of Senior Notes
LAVAL, Quebec, March 12, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") announced today that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has priced its previously announced offering of 9.250% senior notes due 2026 (the "Notes"). The aggregate size of the offering reflects an increase of $250,000,000 from the previously announced offering size of $1,250,000,000 to $1,500,000,000. The Notes were offered at par. The offering is expected to close on or about March 26,
Mar 12, 2018 07:40 pm ET
Valeant Announces Pricing of Private Offering of Senior Notes
LAVAL, Quebec, March 12, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") announced today that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has priced its previously announced offering of 9.250% senior notes due 2026 (the "Notes"). The aggregate size of the offering reflects an increase of $250,000,000 from the previously announced offering size of $1,250,000,000 to $1,500,000,000. The Notes were offered at par. The offering is expected to close on or about March 26, 2018.
Mar 12, 2018 07:31 am ET
Valeant Announces Launch Of Private Offering Of Senior Notes
LAVAL, Quebec, March 12, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") announced today that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has launched an offering of $1,250,000,000 aggregate principal amount of unsecured senior notes due 2026 (the "Notes"). The net proceeds from the offering of the Notes, along with cash on hand, will be used to repurchase $1,250,000,000 aggregate principal amount of outstanding notes pursuant to a tender offer announced earlier to
Mar 12, 2018 07:31 am ET
Valeant Announces Launch Of Private Offering Of Senior Notes
LAVAL, Quebec, March 12, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") announced today that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has launched an offering of $1,250,000,000 aggregate principal amount of unsecured senior notes due 2026 (the "Notes"). The net proceeds from the offering of the Notes, along with cash on hand, will be used to repurchase $1,250,000,000 aggregate principal amount of outstanding notes pursuant to a tender offer announced earlier today, in
Mar 12, 2018 07:30 am ET
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,250,000,000 Outstanding Principal Amount
LAVAL, Quebec, March 12, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly owned indirect subsidiary of Valeant, incorporated in Delaware, announced today that they have commenced cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,250,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstandi
Mar 12, 2018 07:30 am ET
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,250,000,000 Outstanding Principal Amount
LAVAL, Quebec, March 12, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly owned indirect subsidiary of Valeant, incorporated in Delaware, announced today that they have commenced cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,250,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding note
Mar 08, 2018 07:00 am ET
Valeant To Participate At The 2018 Barclays Global Healthcare Conference
LAVAL, Quebec, March 8, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Barclays Global Healthcare Conference in Miami on March 14, 2018, at 8:30 a.m. EDT.
Mar 08, 2018 07:00 am ET
Valeant To Participate At The 2018 Barclays Global Healthcare Conference
LAVAL, Quebec, March 8, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Barclays Global Healthcare Conference in Miami on March 14, 2018, at 8:30 a.m. EDT.
Feb 28, 2018 08:31 am ET
Thinking about buying and selling stock or options in ACADIA Pharmaceuticals, Dicks Sporting Goods, Lowes, Papa John's, or Valeant Pharmaceuticals?
CHICAGO, Feb. 28, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, DKS, LOW, PZZA, and VRX.
Feb 28, 2018 06:00 am ET
Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
LAVAL, Quebec, Feb. 28, 2018 /PRNewswire/ --
Feb 28, 2018 06:00 am ET
Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
LAVAL, Quebec, Feb. 28, 2018 /CNW/ --
Feb 28, 2018 06:00 am ET
Valeant Pharmaceuticals International Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Valeant Pharmaceuticals International Inc (NYSE: VRX) will be discussing their earnings results in their Q4 Earnings Call to be held on February 28, 2018 at 8:00 AM Eastern Time.
Feb 28, 2018 05:45 am ET
Valeant Announces Redemption Of Remaining $71 Million Aggregate Principal Amount Of Its Outstanding 7.00% Senior Unsecured Notes Due 2020
LAVAL, Quebec, Feb. 28, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Valeant Pharmaceuticals International, a wholly owned indirect subsidiary of Valeant, will redeem the remaining $71 million aggregate principal amount of its outstanding 7.00% Senior Unsecured Notes due 2020 (the "Notes"), using cash on hand, on March 30, 2018 and will issue today an irrevocable notice of redemption for the Notes. The Notes were originally issued in 2010.
Feb 28, 2018 05:45 am ET
Valeant Announces Redemption Of Remaining $71 Million Aggregate Principal Amount Of Its Outstanding 7.00% Senior Unsecured Notes Due 2020
LAVAL, Quebec, Feb. 28, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Valeant Pharmaceuticals International, a wholly owned indirect subsidiary of Valeant, will redeem the remaining $71 million aggregate principal amount of its outstanding 7.00% Senior Unsecured Notes due 2020 (the "Notes"), using cash on hand, on March 30, 2018 and will issue today an irrevocable notice of redemption for the Notes. The Notes were originally issued in 2010.
Feb 27, 2018 05:45 pm ET
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
LAVAL, Quebec, Feb. 27, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced its subsidiary has entered into an exclusive license agreement with Kaken Pharmaceutical Co., Ltd., ("Kaken") to develop and commercialize products containing a new chemical entity, KP-470, which is an investigational compound for the topical treatment of psoriasis. If approved, KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease.
Feb 27, 2018 05:45 pm ET
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
LAVAL, Quebec, Feb. 27, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced its subsidiary has entered into an exclusive license agreement with Kaken Pharmaceutical Co., Ltd., ("Kaken") to develop and commercialize products containing a new chemical entity, KP-470, which is an investigational compound for the topical treatment of psoriasis. If approved, KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease.
Feb 16, 2018 09:00 am ET
Ortho Dermatologics Presents An Analysis Of SILIQ™ (Brodalumab) Injection Phase 3 Data On Disease-Related Anxiety And Depression In Patients With Moderate-To-Severe Plaque Psoriasis
Separate Phase 3 Analysis Highlights Long-Term Safety Profile of SILIQ
Feb 14, 2018 06:00 am ET
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL™ Plaque Psoriasis Treatment
PDUFA Date Set for Oct. 5, 2018
Feb 14, 2018 06:00 am ET
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL™ Plaque Psoriasis Treatment
PDUFA Date Set for Oct. 5, 2018
Feb 09, 2018 08:10 am ET
Salix Provides Update on FDA Submission for PLENVU®*
BRIDGEWATER, N.J., Feb. 9, 2018 /PRNewswire/ -- Salix Pharmaceuticals, Ltd. ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), and its partner Norgine B.V. ("Norgine") have received notice that the U.S. Food and Drug Administration (FDA) has extended the PDUFA action date for its review of the New Drug Application for PLENVU®* (NER1006) by three months to May 13, 2018. The PDUFA action date has
Feb 09, 2018 08:10 am ET
Salix Provides Update on FDA Submission for PLENVU®*
BRIDGEWATER, N.J., Feb. 9, 2018 /CNW/ -- Salix Pharmaceuticals, Ltd. ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), and its partner Norgine B.V. ("Norgine") have received notice that the U.S. Food and Drug Administration (FDA) has extended the PDUFA action date for its review of the New Drug Application for PLENVU®* (NER1006) by three months to May 13, 2018. The PDUFA action date has been e
Feb 06, 2018 09:25 am ET
Valeant Will Release Fourth-Quarter And Full-Year 2017 Financial Results On February 28
LAVAL, Quebec, Feb. 6, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") will release its fourth-quarter and full-year 2017 financial results on Wednesday, Feb. 28, 2018. Valeant will host a conference call and live web cast at 8:00 a.m. EST to discuss the results and provide a business update. All materials will be made available on the investor relations section of the Valeant web site prior to the start of the call.
Feb 06, 2018 09:25 am ET
Valeant Will Release Fourth-Quarter And Full-Year 2017 Financial Results On February 28
LAVAL, Quebec, Feb. 6, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") will release its fourth-quarter and full-year 2017 financial results on Wednesday, Feb. 28, 2018. Valeant will host a conference call and live web cast at 8:00 a.m. EST to discuss the results and provide a business update. All materials will be made available on the investor relations section of the Valeant web site prior to the start of the call.
Jan 30, 2018 06:05 am ET
VRX Investor Alert: Kyros Law Files Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors
BOSTON, Jan. 30, 2018 /PRNewswire/ -- Kyros Law Offices is alerting investors of Valeant Pharmaceuticals Intl (NYSE:VRX) that it has filed legal claims on behalf of a group of shareholders against the company for possible securities fraud violations committed by Valeant Pharmaceuticals Intl (NYSE:VRX).
Jan 29, 2018 05:00 pm ET
Safirstein Metcalf LLP and HGT Law Commence a Securities Fraud Action Against Valeant Pharmaceuticals and its Senior Officers on Behalf of Retail Investors - VRX
NEW YORK, Jan. 29, 2018 (GLOBE NEWSWIRE) -- On January 19, 2018, Safirstein Metcalf LLP and HGT Law commenced a shareholder “opt-out” lawsuit (“Lawsuit”) on behalf of a group of retail investors (“Investors”) against Valeant Pharmaceuticals International, Inc....
Jan 25, 2018 02:02 pm ET
Valeant Will Reduce Debt By An Additional $200 Million
LAVAL, Quebec, Jan. 25, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced it put in notice to pay down an additional $200 million of its senior secured term loans, using cash on hand.
Jan 25, 2018 02:02 pm ET
Valeant Will Reduce Debt By An Additional $200 Million
LAVAL, Quebec, Jan. 25, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced it put in notice to pay down an additional $200 million of its senior secured term loans, using cash on hand.
Jan 12, 2018 06:00 am ET
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
PDUFA Date Is Aug. 27, 2018
Jan 12, 2018 06:00 am ET
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
PDUFA Date Is Aug. 27, 2018
Jan 09, 2018 06:00 am ET
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference
Seven Key Products Are Projected to Generate $1 Billion in Sales in 5 Years
Jan 09, 2018 06:00 am ET
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference
Seven Key Products Are Projected to Generate $1 Billion in Sales in 5 Years
Jan 08, 2018 07:00 am ET
Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite™ Vision Enhancement System, Including The Vitesse™ Vitrectomy System
Next-Generation Ophthalmic Surgical Platform Now Available Across Greater Europe
Jan 08, 2018 07:00 am ET
Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite™ Vision Enhancement System, Including The Vitesse™ Vitrectomy System
Next-Generation Ophthalmic Surgical Platform Now Available Across Greater Europe
Jan 03, 2018 08:00 am ET
Valeant Pays Down $300 Million Of Senior Secured Term Loans
LAVAL, Quebec, Jan. 3, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced it has paid down an additional $300 million of its senior secured term loans, using cash on hand.
Jan 03, 2018 08:00 am ET
Valeant Pays Down $300 Million Of Senior Secured Term Loans
LAVAL, Quebec, Jan. 3, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced it has paid down an additional $300 million of its senior secured term loans, using cash on hand.
Jan 03, 2018 07:00 am ET
Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference
LAVAL, Quebec, Jan. 3, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 10, 2018, at 10:30 a.m. PST (1:30 p.m. EST).
Jan 03, 2018 07:00 am ET
Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference
LAVAL, Quebec, Jan. 3, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 10, 2018, at 10:30 a.m. PST (1:30 p.m. EST).
Dec 29, 2017 11:55 am ET
Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation
Valeant Will Pay $96.25 Million to Resolve the Litigation
Dec 29, 2017 11:55 am ET
Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation
Valeant Will Pay $96.25 Million to Resolve the Litigation
Dec 22, 2017 02:02 pm ET
Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness
Clinical Studies Showed 95% Symptom Improvement At One Minute, And Reduced Redness For Up To Eight Hours
Dec 22, 2017 02:02 pm ET
Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness
Clinical Studies Showed 95% Symptom Improvement At One Minute, And Reduced Redness For Up To Eight Hours
Dec 21, 2017 06:02 am ET
VRX Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors
BOSTON, Dec. 21, 2017 /PRNewswire/ -- Kyros Law Offices is alerting investors of Valeant Pharmaceuticals Intl (NYSE: VRX) that it is investigating legal claims against the company for possible securities fraud violations committed by Valeant Pharmaceuticals Intl (NYSE: VRX).
Dec 20, 2017 03:15 pm ET
Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
LAVAL, Quebec, Dec. 20, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that its affiliate has completed the divestiture of the Sprout Pharmaceuticals subsidiary ("Sprout") to Sprout2 Inc., an entity affiliated with certain former shareholders of Sprout, in exchange for a 6% royalty on global sales of ADDYI® (flibanserin) beginning in May 2019. In connection with the sale, Valeant has provided a $25 million loan to fund initial operating expenses.
Dec 20, 2017 03:15 pm ET
Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
LAVAL, Quebec, Dec. 20, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that its affiliate has completed the divestiture of the Sprout Pharmaceuticals subsidiary ("Sprout") to Sprout2 Inc., an entity affiliated with certain former shareholders of Sprout, in exchange for a 6% royalty on global sales of ADDYI® (flibanserin) beginning in May 2019. In connection with the sale, Valeant has provided a $25 million loan to fund initial operating expenses.
Dec 18, 2017 07:00 am ET
Bausch + Lomb Begins Distribution Of VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers
LAVAL, Quebec, Dec. 18, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) ("Valeant") wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, today announced that it has begun distributing VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% to U.S. wholesale pharmaceutical distributors. VYZULTA will be available to patients across the United States through their local pharmacies within the next few days.
Dec 18, 2017 07:00 am ET
Bausch + Lomb Begins Distribution Of VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers
LAVAL, Quebec, Dec. 18, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) ("Valeant") wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, today announced that it has begun distributing VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% to U.S. wholesale pharmaceutical distributors. VYZULTA will be available to patients across the United States through their local pharmacies within the next few days.
Dec 15, 2017 06:35 pm ET
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
LAVAL, Quebec, Dec. 15, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement
Dec 15, 2017 06:35 pm ET
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
LAVAL, Quebec, Dec. 15, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date fo
Dec 07, 2017 07:00 am ET
Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
LAVAL, Quebec, Dec. 7, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Scott A. Hirsch, senior vice president and chief business strategy officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference in New York on Dec. 14, 2017 at 2:00 p.m. EST.
Dec 07, 2017 07:00 am ET
Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
LAVAL, Quebec, Dec. 7, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Scott A. Hirsch, senior vice president and chief business strategy officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference in New York on Dec. 14, 2017 at 2:00 p.m. EST.
Nov 21, 2017 03:15 pm ET
Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment
LAVAL, Quebec, Nov. 21, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has closed its previously announced offering (the "Offering") of $750,000,000 aggregate principal amount of its 5.500% senior secured notes due 2025 (the "Notes"). The Notes are additional notes and form part of the same series as Valeant's existing 5.500% senior secured notes due 2025. Valeant used the net proceeds from the offering of the Notes, along with cash on hand, to prepay (on a pro rata basis) a portion of its outstandi
Nov 21, 2017 03:15 pm ET
Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment
LAVAL, Quebec, Nov. 21, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has closed its previously announced offering (the "Offering") of $750,000,000 aggregate principal amount of its 5.500% senior secured notes due 2025 (the "Notes"). The Notes are additional notes and form part of the same series as Valeant's existing 5.500% senior secured notes due 2025. Valeant used the net proceeds from the offering of the Notes, along with cash on hand, to prepay (on a pro rata basis) a portion of its outstanding Seri
Nov 21, 2017 07:00 am ET
Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference
LAVAL, Quebec, Nov. 21, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Evercore ISI Biopharma Catalyst/Deep Dive Conference in Boston on Nov. 29, 2017 at 11:00 a.m. EST.
Nov 21, 2017 07:00 am ET
Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference
LAVAL, Quebec, Nov. 21, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Evercore ISI Biopharma Catalyst/Deep Dive Conference in Boston on Nov. 29, 2017 at 11:00 a.m. EST.
Nov 16, 2017 01:00 pm ET
TroyGould Advises Haitong International in its $190 Million Acquisition of Obagi Skincare Products Business
LOS ANGELES, Nov. 16, 2017 /PRNewswire/ -- TroyGould advised Haitong International Zhonghua Finance Acquisition Fund I, L.P. (the "Fund") in its $190 million cash acquisition of the Obagi Medical Products business from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX). The Obagi line of premium skincare products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage and are primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals.
Nov 15, 2017 08:00 am ET
Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
First Sponsored Contact Lens Recycling Program Collects More Than 7,000 lbs. of Waste
Nov 15, 2017 08:00 am ET
Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
First Sponsored Contact Lens Recycling Program Collects More Than 7,000 lbs. of Waste
Nov 14, 2017 04:10 pm ET
Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes
LAVAL, Quebec, Nov. 14, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has priced its previously announced offering of $750,000,000 aggregate principal amount of its 5.500% senior secured notes due 2025 (the "Notes"). The Notes will be additional notes and form part of the same series as Valeant's existing 5.500% senior secured notes due 2025. The Notes will be sold to investors at a price of 100.000% of the principal amount thereof plus accrued interest from October 17, 2017, representing a yield t
Nov 14, 2017 04:10 pm ET
Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes
LAVAL, Quebec, Nov. 14, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has priced its previously announced offering of $750,000,000 aggregate principal amount of its 5.500% senior secured notes due 2025 (the "Notes"). The Notes will be additional notes and form part of the same series as Valeant's existing 5.500% senior secured notes due 2025. The Notes will be sold to investors at a price of 100.000% of the principal amount thereof plus accrued interest from October 17, 2017, representing a yield to worst
Nov 14, 2017 09:00 am ET
Ortho Dermatologics Announces Aspire Higher Scholarship Honorees
Scholarship Program Awards Students Across the Country Impacted by Dermatologic Conditions
Nov 14, 2017 09:00 am ET
Ortho Dermatologics Announces Aspire Higher Scholarship Honorees
Scholarship Program Awards Students Across the Country Impacted by Dermatologic Conditions
Nov 13, 2017 07:35 am ET
Valeant Announces Launch of Private Offering of Add-On Secured Notes
LAVAL, QUEBEC, Nov. 13, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has launched an offering of $750,000,000 aggregate principal amount of 5.500% senior secured notes due 2025 (the "Notes"). The Notes will be additional notes and form part of the same series as Valeant's existing 5.500% Senior Secured Notes due 2025. Valeant intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repay (on a pro rata basis) a portion of its outstanding Series F Tranche B Term L
Nov 13, 2017 07:35 am ET
Valeant Announces Launch of Private Offering of Add-On Secured Notes
LAVAL, QUEBEC, Nov. 13, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has launched an offering of $750,000,000 aggregate principal amount of 5.500% senior secured notes due 2025 (the "Notes"). The Notes will be additional notes and form part of the same series as Valeant's existing 5.500% Senior Secured Notes due 2025. Valeant intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repay (on a pro rata basis) a portion of its outstanding Series F Tranche B Term Loan Fac
Nov 10, 2017 07:00 am ET
Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P.
LAVAL, Quebec, Nov. 10, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that it has completed the sale of the Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. (the "Fund") and its affiliate Obagi Cosmeceuticals, LLC. Limited partners of the Fund include industry veterans in other geographic markets, such as China Regenerative Medicine International Limited (SEHK: 8158). Valeant will use approximately $180 million of the net proceeds
Nov 10, 2017 07:00 am ET
Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P.
LAVAL, Quebec, Nov. 10, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that it has completed the sale of the Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. (the "Fund") and its affiliate Obagi Cosmeceuticals, LLC. Limited partners of the Fund include industry veterans in other geographic markets, such as China Regenerative Medicine International Limited (SEHK: 8158). Valeant will use approximately $180 million of the net proceeds from t
Nov 08, 2017 06:02 pm ET
Valeant To Participate At The Stifel 2017 Healthcare Conference
LAVAL, Quebec, Nov. 8, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Stifel 2017 Healthcare Conference in New York on Nov. 14, 2017 at 2:45 p.m. EST.
Nov 08, 2017 06:02 pm ET
Valeant To Participate At The Stifel 2017 Healthcare Conference
LAVAL, Quebec, Nov. 8, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Stifel 2017 Healthcare Conference in New York on Nov. 14, 2017 at 2:45 p.m. EST.
Nov 08, 2017 08:30 am ET
EyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract Surgery
Triggers Milestone Payment under Global Licensing Agreement with Valeant Pharmaceuticals
Nov 07, 2017 07:00 am ET
Valeant Announces Third-Quarter 2017 Results
LAVAL, Quebec, Nov. 7, 2017 /PRNewswire/ --
Nov 07, 2017 07:00 am ET
Valeant Announces Third-Quarter 2017 Results
LAVAL, Quebec, Nov. 7, 2017 /CNW/ --
Nov 06, 2017 07:00 am ET
Valeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
LAVAL, Quebec, Nov. 6, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that its affiliate has entered into an agreement to divest the Sprout Pharmaceuticals subsidiary ("Sprout") to a buyer affiliated with former shareholders of Sprout in exchange for a 6% royalty on global sales of ADDYI® (flibanserin) beginning 18 months from the signing of the sale agreement. In connection with the completion of the sale, Valeant will be released from the ongoing obligations of the original transaction to split future p
Nov 06, 2017 07:00 am ET
Valeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
LAVAL, Quebec, Nov. 6, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that its affiliate has entered into an agreement to divest the Sprout Pharmaceuticals subsidiary ("Sprout") to a buyer affiliated with former shareholders of Sprout in exchange for a 6% royalty on global sales of ADDYI® (flibanserin) beginning 18 months from the signing of the sale agreement. In connection with the completion of the sale, Valeant will be released from the ongoing obligations of the original transaction to split future profits
Nov 02, 2017 05:05 pm ET
Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution), 0.024%
LAVAL, Quebec and SOPHIA ANTIPOLIS, France, Nov. 2, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, and Nicox S.A. (Euronext Paris: FR0013018124, COX), an international ophthalmic company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%). VYZULTA, the first prostaglandin analog with one of its metabolites being nitric oxide (NO), is indicated for the
Nov 02, 2017 05:05 pm ET
Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution), 0.024%
LAVAL, Quebec and SOPHIA ANTIPOLIS, France, Nov. 2, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, and Nicox S.A. (Euronext Paris: FR0013018124, COX), an international ophthalmic company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%). VYZULTA, the first prostaglandin analog with one of its metabolites being nitric oxide (NO), is indicated for the reducti
Nov 02, 2017 08:00 am ET
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment
LAVAL, Quebec, Nov. 2, 2017 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date is June 18, 2018.
Nov 02, 2017 08:00 am ET
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment
LAVAL, Quebec, Nov. 2, 2017 /CNW/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date is June 18, 2018.
Oct 31, 2017 08:00 am ET
Valeant Will Reduce Debt By Additional $125 Million
Valeant Will Exceed $5 Billion Debt Reduction Commitment, Achieving Milestone Earlier Than Anticipated
Oct 31, 2017 08:00 am ET
Valeant Will Reduce Debt By Additional $125 Million
Valeant Will Exceed $5 Billion Debt Reduction Commitment, Achieving Milestone Earlier Than Anticipated
Oct 17, 2017 10:31 am ET
Thinking about buying stock in Delta Airlines, The Goldman Sachs Group, MOMO Inc., Micron or Valeant Pharmaceuticals?
CHICAGO, Oct. 17, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAL, GS, MOMO, MU, and VRX.
Oct 16, 2017 09:34 pm ET
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
LAVAL, Quebec, Oct. 16, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, to purchase up to $1,000,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement
Oct 16, 2017 09:34 pm ET
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
LAVAL, Quebec, Oct. 16, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, to purchase up to $1,000,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date fo
Oct 12, 2017 09:00 am ET
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ™ (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
Data Sets Demonstrating Efficacy and Quality of Life Profile of SILIQ Presented at 2017 Fall Clinical Dermatology Conference
Oct 12, 2017 09:00 am ET
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ™ (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
Data Sets Demonstrating Efficacy and Quality of Life Profile of SILIQ Presented at 2017 Fall Clinical Dermatology Conference
Oct 05, 2017 08:46 pm ET
VRX Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors
BOSTON, Oct. 5, 2017 /PRNewswire/ -- Kyros Law Offices is alerting investors of Valeant Pharmaceuticals Intl (NYSE: VRX) that it is investigating legal claims against the company for possible securities fraud violations committed by Valeant Pharmaceuticals Intl (NYSE: VRX).
Oct 04, 2017 06:16 pm ET
Solta Medical Receives FDA 510(k) Clearance for Thermage FLX™ System, Newest Generation Skin Smoothing Technology
BOTHELL, Wash., Oct. 4, 2017 /PRNewswire/ -- Solta Medical, a division of Valeant Pharmaceuticals North America LLC, announced today that its Thermage FLX™ System received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to non-invasively smooth skin on the face, eyes, and body.
Oct 04, 2017 09:00 am ET
Solta Medical Receives FDA 510(k) Clearance for Thermage FLX™ System, Newest Generation Skin Smoothing Technology
New Thermage FLX™ System Reduces Treatment Time by 25 Percent and Enhances Patient Comfort
Oct 04, 2017 09:00 am ET
Solta Medical Receives FDA 510(k) Clearance for Thermage FLX™ System, Newest Generation Skin Smoothing Technology
New Thermage FLX™ System Reduces Treatment Time by 25 Percent and Enhances Patient Comfort
Oct 03, 2017 09:00 am ET
Bausch + Lomb Introduces Biotrue® ONEday for Astigmatism Contact Lenses in Europe
LAVAL, Quebec, Oct. 3, 2017 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant"), today announced the introduction of Biotrue® ONEday for Astigmatism daily disposable contact lenses in 20 countries in Europe. This latest contact lens advancement provides the convenience of a daily disposable with the innovation of an evolved peri-ballast design for stability and a unique dehydration barrier proven to help the lens maintain 98% of its moisture for up to 16 hours.1
Oct 03, 2017 09:00 am ET
Bausch + Lomb Introduces Biotrue® ONEday for Astigmatism Contact Lenses in Europe
LAVAL, Quebec, Oct. 3, 2017 /CNW/ -- Bausch + Lomb, a leading global eye health company and division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant"), today announced the introduction of Biotrue® ONEday for Astigmatism daily disposable contact lenses in 20 countries in Europe. This latest contact lens advancement provides the convenience of a daily disposable with the innovation of an evolved peri-ballast design for stability and a unique dehydration barrier proven to help the lens maintain 98% of its moisture for up to 16 hours.1
Oct 03, 2017 08:00 am ET
Valeant Will Release Third-Quarter 2017 Financial Results On November 7
LAVAL, Quebec, Oct. 3, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") will release its third-quarter 2017 financial results on Tuesday, Nov. 7, 2017. Valeant will host a conference call and live web cast at 8:00 a.m. EST to discuss the results and provide a business update. All materials will be made available on the investor relations section of the Valeant web site prior to the start of the call.
Oct 03, 2017 08:00 am ET
Valeant Will Release Third-Quarter 2017 Financial Results On November 7
LAVAL, Quebec, Oct. 3, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") will release its third-quarter 2017 financial results on Tuesday, Nov. 7, 2017. Valeant will host a conference call and live web cast at 8:00 a.m. EST to discuss the results and provide a business update. All materials will be made available on the investor relations section of the Valeant web site prior to the start of the call.
Oct 02, 2017 08:47 pm ET
Valeant Announces Pricing Of Private Offering Of Senior Secured Notes
LAVAL, Quebec, Oct. 2, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has priced its previously announced offering of $1,000,000,000 aggregate principal amount of 5.500% senior secured notes due 2025 (the "Notes"). The offering is expected to close on or about October 17, 2017. Valeant intends to use the net proceeds from this offering, along with cash on hand, to repurchase $1,000,000,000 aggregate principal amount of outstanding notes pursuant to a tender offer announced earlier today, including V
Oct 02, 2017 08:47 pm ET
Valeant Announces Pricing Of Private Offering Of Senior Secured Notes
LAVAL, Quebec, Oct. 2, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has priced its previously announced offering of $1,000,000,000 aggregate principal amount of 5.500% senior secured notes due 2025 (the "Notes"). The offering is expected to close on or about October 17, 2017. Valeant intends to use the net proceeds from this offering, along with cash on hand, to repurchase $1,000,000,000 aggregate principal amount of outstanding notes pursuant to a tender offer announced earlier today, including Valeant
Oct 02, 2017 08:36 am ET
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Principal Amount
LAVAL, Quebec, Oct. 2, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant") and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, incorporated in Delaware, announced today that they have commenced cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,000,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes list
Oct 02, 2017 08:36 am ET
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Principal Amount
LAVAL, Quebec, Oct. 2, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant") and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, incorporated in Delaware, announced today that they have commenced cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,000,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in t
Oct 02, 2017 08:35 am ET
Valeant Announces Launch Of Private Offering Of Senior Secured Notes
LAVAL, Quebec, Oct. 2, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has launched an offering of $1,000,000,000 aggregate principal amount of senior secured notes due 2025 (the "Notes"). Valeant intends to use the net proceeds from this offering, along with cash on hand, to repurchase $1,000,000,000 aggregate principal amount of its outstanding 5.375% Senior Notes due 2020 and Valeant Pharmaceuticals International's, a wholly-owned subsidiary of the Company, outstanding 7.000% Senior Notes due 2020
Oct 02, 2017 08:35 am ET
Valeant Announces Launch Of Private Offering Of Senior Secured Notes
LAVAL, Quebec, Oct. 2, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has launched an offering of $1,000,000,000 aggregate principal amount of senior secured notes due 2025 (the "Notes"). Valeant intends to use the net proceeds from this offering, along with cash on hand, to repurchase $1,000,000,000 aggregate principal amount of its outstanding 5.375% Senior Notes due 2020 and Valeant Pharmaceuticals International's, a wholly-owned subsidiary of the Company, outstanding 7.000% Senior Notes due 2020 and 6.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.